Musely delivers personalized compounded treatments for skin, hair, and menopause via asynchronous telemedicine consultations with specialists.
$360MStrategic
A $360M strategic round for a telemedicine + compounding play signals that personalized medicine at scale is finally hitting unit economics that matter to large investors—this isn't about novelty anymore, it's about defensible margins on repeat prescriptions. If you're building in adjacent health verticals (mental health, GI, dermatology), watch how Musely uses this capital: likely expanding specialist network, manufacturing capacity, and insurance reimbursement infrastructure, which are the actual moats in this space, not the app.